Blueprint Medicines (STU:2L9) Total Liabilities : €841.5 Mil (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Blueprint Medicines Total Liabilities?

Blueprint Medicines's Total Liabilities for the quarter that ended in Dec. 2024 was €841.5 Mil.

Blueprint Medicines's quarterly Total Liabilities declined from Jun. 2024 (€820.60 Mil) to Sep. 2024 (€798.74 Mil) but then increased from Sep. 2024 (€798.74 Mil) to Dec. 2024 (€841.50 Mil).

Blueprint Medicines's annual Total Liabilities increased from Dec. 2022 (€788.45 Mil) to Dec. 2023 (€842.39 Mil) but then declined from Dec. 2023 (€842.39 Mil) to Dec. 2024 (€841.50 Mil).

Blueprint Medicines Total Liabilities Historical Data

The historical data trend for Blueprint Medicines's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Total Liabilities Chart

Blueprint Medicines Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

204.11

249.12

788.45

842.39

841.50

Blueprint Medicines Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															842.39	669.57	820.60	798.74	841.50

Blueprint Medicines Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Blueprint Medicines's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	249.06	+	(393.31	+	6.4859999999999
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	192.64	+	0	+	0)
	=	841.5

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	1126.721	-	285.225
	=	841.5

Blueprint Medicines's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	249.06	+	(393.31	+	6.4859999999999
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	192.64	+	0	+	0)
	=	841.5

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	1126.721	-	285.225
	=	841.5

Blueprint Medicines Total Liabilities Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Blueprint Medicines Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (STU:2L9) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

BPMC:USA 0HOJ:UK 2L9:Germany

Address

45 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.blueprintmedicines.com

Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.

Blueprint Medicines Headlines

No Headlines